Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07546357

AIManage Using an AI-driven CDS and Chatbot

The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH.

The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Diabetes Body Weight Chemically-Induced Disorders Diabetes Mellitus Drug-Related Side Effects and Adverse Reactions Endocrine System Diseases Glucose Metabolism Disorders Medication Side Effects Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NYU Langone Health

New York, 10016, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Provider Eligibility Criteria (Phase 1)

  • Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics,
  • Provide care to at least 5 patients prescribed an IMM.

Patient Eligibility Criteria (Phase 1)

  • (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months;
  • Fluency in English or Spanish;
  • Be willing to send/receive text messages; and
  • Be > 18 years of age.

Exclusion criteria

Provider Exclusion Criteria (Phase 1) • Refuse to participate

Patient Exclusion Criteria (Phase 1)

  • Refuse or are unable to provide informed consent;

Treatment and study plan

AIManage

Other

GenAI-powered CDS tool that provides a range of IMM management services, such as personalized guidance for patients on side effects management and clinical advisement to optimize dose titrations.

Primary outcomes

  1. Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness

    Time frame: Day 1 (60 minutes)

    In Phase 1, qualitative data regarding perceived usefulness will be collected.

  2. Percentage of Patients who Complete Qualitative Measure - Perceived Usability

    Time frame: Day 1 (60 minutes)

    In Phase 1, qualitative data regarding perceived usability will be collected.

  3. Percentage of Patients who Complete Qualitative Measure - Perceived Use Challenges

    Time frame: Day 1 (60 minutes)

    In Phase 1, qualitative data regarding perceived use challenges will be collected.

  4. Percentage of Patients who Complete Qualitative Measure - Perceived Value

    Time frame: Day 1 (60 minutes)

    In Phase 1, qualitative data regarding perceived value will be collected.

Study contacts

Contact information is provided by the study sponsor or research team.

Elizabeth Stevens, PhD, MPH

CONTACT

[email protected]

646-501-2558

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

AIManage: Using an AI-driven CDS and Chatbot for the Management of Patients on Incretin Mimetic Medications

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Apr 22, 2026
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.